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The incidence of mTOR marker in tracheal adenoid cystic 
carcinoma by immunohistochemical staining
Abstract
Introduction: There is an association between the activation of mammalian target of rapamycin (mTOR) signaling and aggressive 
tumor growth in multiple forms of cancer, including adenoid cystic carcinoma (ACC). ACCs are uncommon yet a malignant form 
of neoplasms that arises within the secretory glands. Therefore, the aim of this study was to investigate the increase of mTOR in 
the ACC tumors in order to survey the possibility of treating these tumors with mTOR inhibitors.
Material and methods: Samples from known cases of the lung and tracheal ACC were retrieved from the archives of the pa-
thology department of Masih Daneshvari hospital, and immunohistochemical (IHC) staining for mTOR was performed on them. 
After preparation of the blocks with specific antibodies, tumor cells with cytoplasmic and/or nuclear expression of mTOR were 
considered as positive cells by applying a specific scoring method introduced in this study.
Results: The paraffin blocks of 26 patients were surveyed and the IHC marker of mTOR was positive in the tumors of 10 patients 
(38.5%). Out of 10 mTOR positive cases, 5 were females and 5 were males. The primary site of the surveyed tumors was the 
trachea and bronchus in 12 cases (46%), salivary glands in 7 individuals (27%), and lung tissue in 7 cases (27%), and there was no 
significant correlation between the primary site of the ACC tumors and the existence of the mTOR markers in them (P = 0.67). From 
all cases, 13 patients (50%) had cribriform and tubular cells without solid components, 9 cases (34.6%) had cribriform and tubular 
with less than 30% of solid components, and 4 cases (15.4%) had cribriform and tubular cells with more than 30% of solid com-
ponents. There was no significant difference between the morphologies and the existence of mTOR markers in them (P = 0.741).
Conclusions: As the incidence of mTOR markers is seen in patients with tracheal ACC, evaluation and scoring of mTOR in these 
persons can be helpful as further studies can distinguish the use of it in the treatment of the disease.
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Introduction
The mammalian target of rapamycin (mTOR) 
as a serine/threonine kinase belonging to the 
phosphoinositide 3 kinase-related kinase (PIKK) 
family is expressed in most mammalian cells 
to control growth and metabolism [1–5]. The 
mTOR1 and mTOR2 complexes are involved in 
normal cell growth and developmental process 
and are crucial for its viability by regulating the 
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kinases of the AGC family, protein synthesis and 
autophagy [6]; accordingly, their dysregulation 
is implicated in the pathophysiology of several 
diseases, including cancer, type 2 diabetes, and 
neurodegeneration [7]. 
There is a correlation between the activation 
of mTOR signaling and aggressive tumor growth 
in many cancers [8]. As a matter of fact, after the 
hyperactivation of mTOR signaling, the tumors 
grow at an increased rate and they are less likely 
to disappear because of an increased amount of 
protein synthesis and inhibition of autophagy 
[9, 10]. Also, the activated mTOR pathway helps 
proliferation, migration, and survival of tumor 
cells, which increases the tumor invasiveness 
[11]. In addition, this pathway reduces the tumor 
cells sensitivity to chemotherapy and hormonal 
treatment [12]. Hence, inhibition of its activity 
increases the chemotherapy effectiveness and 
improves the outcome of the treatment of these 
tumors [13]. The natural inhibitor of mTOR is 
rapamycin. Temsirolimus and everolimus are 
other important inhibitors whose effectiveness 
in the treatment of different cancers has been 
proven [13, 14].
Adenoid cystic carcinoma (ACC) as an ag-
gressive neoplasm of salivary glands is the 
second most common primary malignancy of 
tracheal neoplasm, in whose pathophysiology the 
mTOR pathway may be involved [15]. Although 
the incidence of this tumor is low, about 90% of 
them are malignant [16]. The treatment of the 
patients with ACC includes surgical resection of 
the tumors with their margins and reconstruc-
tion, chemotherapy, and radiotherapy [17], and 
as mentioned, if the marker of the mTOR pathway 
is high in these tumors, using the mTOR inhib-
itors may increase the chemotherapy effective-
ness. The aim of this study was to investigate the 
incidence of mTOR in the ACC tumors in order 
to survey the possibility of treating them with 
mTOR inhibitors.
Material and methods
The samples of the Pathology department of 
Masih Daneshvari hospital were searched for ACC 
tumors of the trachea with diagnosis confirmed 
between 2010 and 2014, with the approval of the 
institutional review board. Then, paraffin blocks 
of known cases of the ACC of the lung and tra-
chea (primary and metastatic carcinoma) were 
retrieved from the archives of the department and 
reviewed by two different pathologists without 
knowledge of the initial diagnosis.
Immunohistochemistry
Formalin-fixed paraffin blocks of known cases 
of the ACC of the lung and trachea were used in 
our study. In brief, following dewaxing, washing 
and rehydration of the slides through xylene and 
graded alcohols, microwave heating in citrate buf-
fer were used for antigen retrieval. Endogenous 
peroxidase was blocked in ChemMate peroxi-
dase-blocking solution (Dako). Phospho-mTOR 
(Ser2448) — cell signalling #2976, monoclonal 
rabbit, dilution 1:50 was the main antibody and 
EnVision™ Dual Link System (Dako) was used as 
a detection system [18].
A positive immunohistochemical reaction 
was indicated by brown cytoplasmic and/or 
nuclear staining. Cases were scored on the basis 
of the visually estimated percentage of tumor 
cells with positive cytoplasmic and/or nuclear 
staining.
Scoring
After the staining, tumor cells with cytoplas-
mic and/or nuclear expression of mTOR were 
considered as positive cells according to the 
scoring method presented below:
1. In the regions with the highest density of
positive cells for each slide, the percentage of
positive cells in 5 separate fields which had
≥ 1000 adjacent cells were counted and scored
as: percentage of positive cells less than 1%:
0, between 1% and 25%: 1, 26% to 50%: 2,
51% to 75%: 3, 76% to 100: 4 (Table 1).
2. The color intensity of the stained blocks was
scored based on color intensity as follows:
lack of brown 0, mild: 1, moderate: 2, severe:
3 (Table 2).
3. The two obtained points for each tissue
were multiplied to calculate the final scores
(max. score: 12) and the final scores were
categorized into: 0–1: negative for mTOR,
2–3: weakly positive for mTOR, 4–6: positive
Table 1. Scoring of the percentage of positive cells
The percentage of positive cells Score
< 1% 0
1–25% 1
26–50% 2
51–75% 3
76–100% 4
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for mTOR, 7-12: strongly positive for mTOR 
(Table 3).
4. For statistical analysis, the samples were
divided into two groups: positive for mTOR
marker (final score > 3) and negative for
mTOR marker (final score ≤ 3).
Statistical analysis
The data was analyzed using SPSS V22 soft-
ware and an ANOVA test followed by a Chi-square 
test, a T-test and a Fisher’s exact test.
Results
In the study, a total number of 32 patients 
with adenoid cystic carcinoma were reviewed by 
pathologists. Six patients were excluded due to 
the prior history of radiotherapy. Finally, the par-
affin blocks of 26 subjects were surveyed (Table 4) 
and the immunohistochemistry (IHC) marker of 
the mTOR expression was positive in the tumors 
of 10 patients (38.5%). From 10 mTOR positive 
cases in immunohistochemistry surveys, 5 were 
females and 5 were males. Also, negative cases for 
mTOR were seen equally among men and women. 
Therefore, there was no difference between men 
and women in the existence of mTOR markers in 
the ACC tumors (Table 4). 
The mean age of patients was 53.12 ± 15.3 and 
57.7% of them (n = 15) had a mean age of 50 years 
or older (Table 4). There was no significant cor-
relation between the existence of mTOR mark-
ers in ACC tumors and the age of the patients 
(P = 0.48).
The primary site of the surveyed tumors was 
the trachea and bronchus in 12 cases (46%), sal-
ivary glands in 7 cases (27%), and lung tissue in 
7 cases (27%) (Table 4). The frequency of mTOR 
positive patients based on the primary site of 
the tumors are summarized in Table 5. The per-
centage of mTOR positive cases in tracheal and 
bronchial tumors was 41.7%, in salivary gland 
tumors was 28.6%, and in lung tumors was 42.8%. 
In the study, there was no significant correlation 
between the primary site of the ACC tumors and 
the existence of mTOR markers (P = 0.67).
Table 2. Scoring of the color intensity of the tissue 
 fragments
Color intensity Score
Lack of brown 0
Mild 1
Moderate 2
Severe 3
Table 3. The existence of mTOR markers according to 
the final scores
Final score The existence of mTOR
0, 1 Negative for mTOR
2, 3 Weakly positive for mTOR (+)
4–6 Positive for mTOR (++)
7–12 Strongly positive for mTOR (+++)
Table 4. Demographic information, tumor location, mTOR existence and morphology of tumor cells
Variable Number of ACC Percentage P value*
Gender Male
Female
13
13
50
50
1
Age < 50 years old
> 50 years old
11
15
42.3
57.7
0.48
The primary site 
of the tumors
Trachea and bronchus
Salivary glands
Lung
12
7
7
46
27
27
0.67
Type of tumor Primary
Metastatic
20
6
77
23
0.457
mTOR existence Positive
Negative
10
16
38.5
61.5
N/A
Morphology Morphology**
Morphology***
Morphology****
13
9
4
50
34.6
15.4
0.741
*P value for comparing variables based on the existence of mTOR marker; **cribriform and tubular cells without solid components; ***cribriform and tubular with less 
than 30% of solid components; ****cribriform and tubular cells with more than 30% of solid components
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Among these tumors, 20 tumors (77%) were 
the primary tumors and only 6 of them (23%) 
were metastases from other sites (4 cases with 
metastasis from salivary glands and 2 cases with 
metastasis from the trachea) (Table 4). From the 
mTOR positive cases, 8 of them (40%) were prima-
ry tumors and only 2 of them (33.3%) were met-
astatic tumors (Table 6). There was no significant 
difference between metastatic or primary tumors 
in the existence of mTOR markers (P = 0.457).
In terms of the morphology of tumor cells, 
13 cases (50%) had cribriform and tubular cells 
without solid components (morphology 1), 9 cases 
(34.6%) had cribriform and tubular with less than 
30% of solid components (morphology 2), and 
4 cases (15.4%) had cribriform and tubular cells 
with more than 30% of solid components (mor-
phology 3). There was no significant difference 
between different morphologies in the existence 
of mTOR markers (P = 0.741). Different morpholo-
gies of the ACC tumor cells are shown in Figure 1.
Also, in the study, we investigated the site of 
the staining (Figure 2) in the tumor cells (cyto-
plasmic, nuclear, or both cytoplasmic and nucle-
ar) based on the three types of morphology - the 
results are summarized in Table 7. Out of 10 pa-
tients who were considered positive (3 < final 
score), 4 had nuclear staining, 4 had cytoplasmic 
staining and 2 had both nuclear and cytoplasmic 
staining. Also, out of the 16 patients who were 
considered negative (3 > final score), 8 had no 
staining, 7 had cytoplasmic staining, 1 had both 
nuclear and cytoplasmic staining, but none had 
nuclear staining. 
Discussion
This study was conducted to investigate the 
incidence of mTOR in the paraffin blocks of the 
patients with ACC tumors using immunohisto-
chemistry technique. According to our surveys, 
the IHC marker of mTOR expression was posi-
tive in the tumors of 10 cases (38.5%) out of the 
26 surveyed. In a similar study by Wang Li et al., 
the mTOR marker in non-small cell lung cancer in 
43.5% of 78 patients was positive [19]. Also, in the 
study by Meiling Wen et al. about the importance 
of mTOR expression in patients with colon cancer, 
out of 106 subjects with this cancer, 80 patients 
(75.5%) were mTOR positive [20]. It seems that the 
differences can be related to the different sample 
sizes, which suggests the need for more studies 
in this regard with larger sample sizes.
In addition, out of 10 mTOR positive patients 
in this study, 5 were females and 5 were males, 
and there was no difference between men and 
women in the expression of mTOR. The mean 
age of the patients in the study was 53.12 years 
and there was no significant correlation between 
the existence of mTOR markers and the age of the 
patients (P = 0.48). These results are consistent 
with the outcomes of the study by Wang et al. 
on the expression of mTOR in 210 patients with 
lung cancer and the results of the study of Meiling 
Wen et al.; in both studies, it has been shown that 
there is no significant relationship between the 
expression of mTOR and age and sex [19, 20].
In our study, 20 patients with ACC (77%) 
had primary tumors and the mTOR marker was 
Table 5. The frequency of mTOR positive cases based on the primary site of the tumors
IHC survey Trachea 
and bronchus
Percentage Salivary 
glands
Percentage Lung Percentage P value
Positive 5 41.7 2 28.6 3 42.8 0.67
Negative 7 58.3 5 71.4 4 57.2
Total 12 100 7 100 7 100
IHC — immunohistochemical
Table 6. The frequency of mTOR positive cases based on their type 
IHC survey Primary tumors Percentage Metastatic tumors Percentage P value
Positive 8 40 2 33.3 0.457
Negative 12 60 4 66.6
Total 20 100 7 100
IHC — immunohistochemical
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positive in 8 of them (40%), 6 patients had a met-
astatic tumor, and the mTOR marker was positive 
in 2 cases (33.3%). Hence, there was no significant 
difference between metastatic or primary tumors 
in the existence of mTOR markers (P = 0.457), 
although more studies with larger sample sizes 
are required.
The ACC tumors were divided into three 
groups according to the morphology: cribriform 
and tubular without solid components, cribri-
form and tubular with less than 30% of solid 
components, and cribriform and tubular with 
more than 30% of solid components [21]. Of the 
26 patients, 13 cases were in the first group with 
6 (42.8%) mTOR positive patients, 9 in the second 
group with 3 (37.5%) mTOR positive cases and 
4 in the third group with 1 (25%) mTOR positive 
case. Although this difference is not statistically 
significant in our study, it seems that there is a re-
verse correlation between the percentage of solid 
components and the existence of mTOR markers, 
Figure 1. Different morphologies of the ACC tumor cells. A. and B. Cribriform; C. Solid; and D. Tubular
A
C
B
D
and according to the direct correlation between 
the high percentage of the solid component and 
the grade of cancer, it can be deduced that more 
invasive ACCs with higher grades have lower 
incidence of mTOR markers. This is consistent 
with the results of the study by Wang Li et al. that 
has shown that low-grade and moderate-grade 
neuroendocrine tumors have a higher incidence 
of mTOR markers than high-grade tumors [19]. 
Although the incidence of tracheal ACC 
tumors is low, about 90% of them are malignant 
[22], and their diagnosis is delayed due to the 
slow growth rate, and their atypical symptoms 
and patients are misdiagnosed with asthma or 
bronchitis [23]. The everolimus and temsiro-
limus are approved as anticancer drugs which 
targeted the inhibition of the mTOR pathway in 
the clinic [24].
The limitation to the study that is worth men-
tioning was the restricted number of cases that 
was due to the rare incidence of the disease. Also, 
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Table 7. The site of the staining of tumor cells and the color intensity distinguishing between positive and negative cases
Variable ACC Total
Morphology 1 Morphology 2 Morphology 3 26
The site of the staining 
in the positive cases
Negative
Cytoplasmic
Nuclear
both cytoplasmic and nuclear
–
2
2
2
2
1
–
–
1
–
2
4
2
2
Total 6 3 1 10
The site of the staining 
in the negative cases
Negative
Cytoplasmic
Nuclear
both cytoplasmic and nuclear
4
4
–
–
3
1
–
1
1
2
–
–
8
7
–
1
Total 8 5 3 16
Color intensity 
in the positive cases
Lack of brown
Mild
Moderate
Severe
–
–
5
–
–
–
4
–
–
–
1
–
–
–
10
–
Total 5 4 1 10
Color intensity 
in the positive cases
Lack of brown
Mild
Moderate
Severe
4
6
–
–
3
–
1
–
1
1
–
–
8
7
1
–
Total 10 4 2 16
ACC — adenoid cystic carcinoma
A
C
B
D
Figure 2. Different sites of the staining in the tumor cells. A. Negative; B. Mild cytoplasmic; C. Mild nuclear, and D. Moderate nuclear
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Table 8. The percentage of positive cells in slides distinguishing between positive and negative cases and final scores for 
all cases
Variable ACC Total
Morphology 1 Morphology 2 Morphology 3 26
The percentage of positive cells 
in the slide for positive cases
Total 
< 1%
1– 25%
26– 50%
51– 75%
76– 100%
–
–
2
1
2
5
–
–
2
2
–
4
–
–
1
–
–
1
–
–
5
3
2
10
The percentage of positive cells 
in the slide for negative cases
Total 
< 1%
1–25%
26–50%
51–75%
76–100%
4
4
2
–
–
10
3
1
–
–
–
4
1
1
–
–
–
2
8
6
2
–
–
16
Final scores for all cases
Total
0, 1 (–)
2, 3 (+)
4–6 (++)
7–12 (+++)
7
1
3
2
13
4
1
4
–
9
2
1
1
–
4
13
3
8
2
26
the study only surveyd patients of one ethnicity. 
Future research with larger and multiethnic data 
pool can better assess these findings.
Conclusion
For the first time in Iran, the IHC staining 
was used to investigate the mTOR pathway in the 
ACC tumors. The site of the staining in the tumor 
cells (nuclear, cytoplasmic, or both), the intensity 
of coloring, and the percentage of positive tumor 
cells were used to present a unique scoring sys-
tem to be applied in the investigation of mTOR 
markers in ACC tumors. The mTOR can be used 
as a target for the treatment of the cancer, and 
in this study, the presence of mTOR marker in 
some of the ACC patients has been shown. Thus, 
further evaluation of using mTOR as suggestive 
indicator for targeted therapy of ACCs and the 
effectivity of mTOR inhibitors in the treatment 
for these tumors are recommended.
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